The latest big bet in precision medicine is near
Drug companies have made fortunes in the field of targeted cancer therapies, designing molecules that home in on ever-rarer alphanumeric mutations and charging impressive amounts of money for drugs that help small numbers of patients. Turning Point Therapeutics, on the other hand, is pitching a drug it believes can beat out competitors by hitting a few of those mutations at the same time. And soon we’ll know if that’s true.
In the coming weeks, Turning Point expects to have data from a trial testing its drug, repotrectinib, in six patient cohorts, including those with the cancer-related mutations ROS1 and NTRK, plus patients whose tumors have endured despite prior therapy.
If everything goes to plan, Turning Point will have essentially built a better mousetrap in oncology, creating a treatment that can compete with lucrative drugs from Pfizer, Roche, and Eli Lilly. If not, the company’s $2.5 billion market cap probably won’t survive. We should know either way before the end of September.
In the coming weeks, Turning Point expects to have data from a trial testing its drug, repotrectinib, in six patient cohorts, including those with the cancer-related mutations ROS1 and NTRK, plus patients whose tumors have endured despite prior therapy.
If everything goes to plan, Turning Point will have essentially built a better mousetrap in oncology, creating a treatment that can compete with lucrative drugs from Pfizer, Roche, and Eli Lilly. If not, the company’s $2.5 billion market cap probably won’t survive. We should know either way before the end of September.
.png)
No hay comentarios:
Publicar un comentario